Nutex Health Inc. (NUTX) intrinsic value & 10-year financials
Nutex Health Inc. (NUTX) has a Graham intrinsic value of $348.10 per share. At $186.10 on Oct 17, 2026, the stock trades 47% below that value. Over the last 10 fiscal years revenue grew 273.4% a year to $875.3M, with an average return on invested capital of 1185.7%.
- Graham intrinsic value
- $348.10
- Share price (Oct 17, 2026)
- $186.10
- Price vs Graham value
- 47% below
- Market cap
- $1.3B
- Revenue (FY2025)
- $875.3M
- Revenue growth (10-yr CAGR)
- 273.4%
- ROIC (10-yr avg)
- 1185.7%
- Free cash flow (FY2025)
- $245.6M
NUTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $875.3M | $70.8M | $10.48 | $245.6M | 31.5% | 31.5% |
| FY2024 | $479.9M | $52.2M | $9.71 | $20.8M | 27.2% | 27.8% |
| FY2023 | $247.6M | -$45.8M | -$0.07 | -$8.2M | -12.8% | -9.1% |
| FY2022 | $219.3M | -$424.8M | -$0.67 | $36.0M | -185.4% | -141.6% |
| FY2021 | $18.8M | -$13.7M | $0.22 | -$43.6M | -48.0% | -6.7% |
| FY2020 | $1.6M | -$5.7M | $0.18 | -$1.5M | -327.1% | 7199.7% |
| FY2019 | $1.4M | -$7.1M | — | -$4.1M | -504.8% | 4598.5% |
| FY2018 | $1.4M | -$950.1K | — | -$480.0K | -61.5% | 63.8% |
| FY2017 | $23.2K | $582.1K | — | — | -24574.5% | -33.3% |
| FY2016 | $0 | -$7.4M | — | — | — | 126.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Nutex Health Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Nutex Health Inc. has earned high returns on invested capital, averaging 17.7% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Over the decade, Nutex Health Inc. shows that management has aggressively returned capital to shareholders by retiring 83.0% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Nutex Health Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $348.10 per share.